海普瑞(002399.SZ)随A股同业弹逾4% 惟在港上市H股海普瑞(09989.HK)持续「潜水」
国务院金融稳定发展委员会开会促请打击资本市场违法行为,银监会周未发文严禁金融业违规资金流入股市及楼市,以及银行和保险公司参与场外配资。沪指及深成继上周五分别由两年半高位及逾五年半回吐近1.9%及0.6%结束八连涨後,前者今天低开後反覆回升0.8%报3,410,後者续升2%报13,952。板块方面,生物疫苗板块急涨逾5%居榜首。
於深圳上市的海普瑞A股(002399.SZ)也随同业弹4.1%报27元人民币。不过,於本港上市海普瑞药业(09989.HK)上市第四天,股价持续「潜水」,继首挂日高见18.68元无以为继,今天更一度跌至17元才喘定,曾反弹至17.44元,现造17.24元,续跌1.4%,成交474万股。
海普瑞是内地领先制药公司,在制药领域、创新生物科技领域及CDMO领域拥有全球业务。根据弗若斯特沙利文资料,按2019年全球销售额计,海普瑞是内地最大及全球第三大依诺肝素钠注射液生产商及销售商,占据6.5%全球市场份额。海普瑞今次来港发发售逾2.2亿股H股,并已引入OrbiMed Funds、AVICT、欧万达基金、3W及Anlan Funds为基石投资者,合共认购4,630.75万股H股(设有6个月禁售期);其中10%公开发售获逾68倍超购,已启动回拨机制占比增至40%,认购一手中签率40%;股份以招股范围(18.4-20.6元)下限定价,料集资净额约38.06亿元,主要用作还债、於欧洲及其他市场发展营销网络和基建、提升研发生产能力及用於创新药投资等。上市联席保荐人大摩及高盛。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.